VER-50589 (CAS 747413-08-7)
QUICK LINKS
VER-50589 is an isoxazole compound that inhibits Hsp90, a heat shock protein that acts as a molecular chaperone with roles in protein folding, cell signaling, and cancer.VER-50589 is an isoxazole compound that may act to inhibit Hsp90 with an IC50 value of 21 nM. It produces a mean cellular antiproliferative GI50 value of 78 nM when tested against a human cancer cell line panel. Consistent with inhibition of Hsp90, VER-50589 has also been shown to induce the expression of HSP27 and Hsp72 while reducing the client proteins C-RAF, B-RAF, survivin, and PRMT5, causing cell cycle arrest and apoptosis. VER-50589 shows favorable pharmacokinetics and impairs tumor growth in animals. Importantly, glioblastoma cells do not acquire resistance to VER-50589 and resistance to other Hsp90 inhibitors does not produce cross-resistance to VER-50589.
VER-50589 (CAS 747413-08-7) References
- Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. | Sharp, SY., et al. 2007. Mol Cancer Ther. 6: 1198-211. PMID: 17431102
- Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. | Gaspar, N., et al. 2009. Cancer Res. 69: 1966-75. PMID: 19244114
- A mammalian functional-genetic approach to characterizing cancer therapeutics. | Jiang, H., et al. 2011. Nat Chem Biol. 7: 92-100. PMID: 21186347
- A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes. | Gillan, V., et al. 2014. PLoS Negl Trop Dis. 8: e2699. PMID: 24551261
- Discovering Anti-Cancer Drugs via Computational Methods. | Cui, W., et al. 2020. Front Pharmacol. 11: 733. PMID: 32508653
- Isocotoin suppresses hepatitis E virus replication through inhibition of heat shock protein 90. | Nimgaonkar, I., et al. 2021. Antiviral Res. 185: 104997. PMID: 33326835
- Evolution of kinase polypharmacology across HSP90 drug discovery. | Antolin, AA., et al. 2021. Cell Chem Biol. 28: 1433-1445.e3. PMID: 34077750
- Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study. | Oh, KK., et al. 2021. Med Hypotheses. 155: 110656. PMID: 34399157
- The Role of the Heat-Shock Proteins in Esophagogastric Cancer. | Tustumi, F., et al. 2022. Cells. 11: PMID: 36078072
- Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance. | Zhang, J., et al. 2022. Cells. 11: PMID: 36139353
- Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications. | Ardestani, M., et al. 2022. Pharmaceutics. 14: PMID: 36297655
- Multitarget and Multipathway Regulation of Zhenqi Fuzheng Granule against Non-Small Cell Lung Cancer Based On Network Pharmacology and Molecular Docking. | Zhou, Y., et al. 2022. Evid Based Complement Alternat Med. 2022: 5967078. PMID: 36437827
- Antiviral activity of the HSP90 inhibitor VER-50589 against enterovirus 71. | Zhu, G., et al. 2023. Antiviral Res. 211: 105553. PMID: 36737007
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VER-50589, 500 µg | sc-296692 | 500 µg | $70.00 | |||
VER-50589, 1 mg | sc-296692A | 1 mg | $110.00 |